Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo

• Status: Recruiting
• Trial end date: 2021-08-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present work is to evaluate the efficacy and safety of diphenylcyclopropenone (DPCP) as a depigmenting therapy in extensive Vitiligo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University

Criteria

Inclusion Criteria:

1. Adult patients of both genders ≥ 18 years.

2. Vitiligo universalis patients with cosmetically unacceptable residual pigmentation.

3. Extensive vitiligo vulgaris ≥ 50% body surface area (BSA) involvement with areas recalcitrant to repigmentation on exposed skin with consequent psychological impairment.

Exclusion Criteria:

1. Children.

2. Early, localized, segmental or any vitiligo case responsive to repigmentation treatment.

3. Pregnant and lactating females.

4. Patients with history of any malignancy.

5. Patients with active infectious or inflammatory dermatoses.

6. Patients with a history of hypertrophic scars or keloids.

7. Patients suffering from cardiac, hepatic or renal disorders.